S&P/TSX composite up as energy stocks rise, U.S. markets in the red
TORONTO – Strength in energy stocks as the price of oil climbed helped Canada's main stock index move up in late-morning trading, while U.S. stock markets fell.
The S&P/TSX composite index was up 66.16 points at 26,241.21.
In New York, the Dow Jones industrial average was down 226.19 points at 42,043.88. The S&P 500 index was down 14.77 points at 5,896.92, while the Nasdaq composite was down 6.76 points at 19,107.01.
The Canadian dollar traded for 73.02 cents US compared with 72.68 cents US on Friday.
The July crude oil contract was up US$1.98 at US$62.77 per barrel and the July natural gas contract was up 26 cents US at US$3.71 per mmBTU.
The August gold contract was up US$83.20 at US$3,398.60 an ounce and the July copper contract was up 22 cents US at US$4.90 a pound.
Monday Mornings
The latest local business news and a lookahead to the coming week.
This report by The Canadian Press was first published June 2, 2025.
Companies in this story: (TSX:GSPTSE, TSX:CADUSD)
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Cision Canada
26 minutes ago
- Cision Canada
AI in Healthcare Just Crossed a Tipping Point. Investors Are Watching These Names
Issued on behalf of Avant Technologies Inc. VANCOUVER, BC, June 4, 2025 /CNW/ -- Equity Insider News Commentary – Generative AI is transforming healthcare faster than almost any other sector, according to a new McKinsey report. In a March survey of senior leaders across payers, providers, and healthcare services groups, 85% said they're actively using or exploring the technology. McKinsey's Global Institute estimates Gen AI could unlock $60–110 billion in annual value across pharma and medical products alone. With more AI pilot programs running than ever before, the tech world is racing to meet demand — including new efforts from Avant Technologies, Inc. (OTCQB: AVAI), Medtronic plc (NYSE: MDT), Butterfly Network, Inc. (NYSE: BFLY), Oracle Corporation (NYSE: ORCL), and Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX). Investor capital is pouring into AI-driven healthcare, with Pittsburgh-based Abridge AI Inc. pulling in $300 million at a $5.3 billion valuation. While several private players are making headlines, public markets are also heating up. Statista now projects the global AI healthcare market will soar from $11 billion to $188 billion by 2030 — a staggering 37% compound annual growth rate. Avant Technologies, Inc. (OTCQB: AVAI), in partnership with Ainnova Tech, is entering the final prototyping stage of a proprietary, automated retinal imaging device — marking a potential turning point in the companies' shared push toward AI-powered early diagnostics. The new device is designed to operate hands-free and feed imaging data directly into the Vision AI platform, enabling near-instant risk reports without expensive equipment or trained personnel. The companies say the camera, developed under their joint venture Ai-nova Acquisition Corp. (AAC), is expected to cost a fraction of legacy fundus cameras. By combining affordability with automation, the device could expand screening access across primary care clinics and emerging-market providers that have traditionally been priced out of ophthalmic diagnostics. "The cost of a fundus camera has always been a barrier to entry in this market," said Vinicio Vargas, CEO at Ainnova and board member of AAC. "Our low-cost camera, which is a fraction of the cost of currently available cameras on the market, should allow us to not only enter the market, but to capture a large share of the market." But hardware is only half the story. The new camera is being built to integrate seamlessly with Vision AI, Ainnova's diagnostic platform that uses retinal imaging, vital signs, and basic lab inputs to assess risk for a range of diseases. Already in use across clinical sites in Latin America, Vision AI currently supports risk scoring for diabetic retinopathy, glaucoma, age-related macular degeneration, cardiovascular disease, type 2 diabetes, liver fibrosis, and chronic kidney disease. "Another significant advantage will be that our camera will be seamlessly packaged together with our Vision AI platform, allowing us to refer more patients in less time and accurately to medical specialists," added Vargas. "Also, one of our objectives is to integrate other technologies to this preventive screening, expanding the scope from only diabetic patients to patients who have other risk factors and want to prevent other diseases from a more complete approach." The development comes at a critical time for Avant, which is in active talks to acquire Ainnova outright — a move that would consolidate leadership, simplify operations, and unify the companies under one roof ahead of a planned FDA pre-submission meeting scheduled for next month. The two companies already operate jointly through AAC, which holds global licensing rights to Ainnova's technology portfolio and serves as the commercialization engine for Vision AI and all future device deployments. While Vision AI remains compatible with third-party imaging equipment, the decision to design proprietary hardware marks a strategic shift toward product exclusivity — giving Avant greater control over the end-to-end user experience and enhancing its defensibility in a competitive early diagnostics landscape. Also in development are additional platform modules, including a patented dementia detection tool that combines a five-minute blood test with AI-trained algorithms. Although that technology remains in evaluation, the core platform continues to expand its reach and functionality — evolving from a retinal-focused application into a broader engine for predictive healthcare. "Our purpose is to create the future of early disease detection in an accessible way, so that patients can get a preventive check-up anywhere, at a low cost, and easily," said Vargas in a previous statement. "We want to prevent patients with risk factors from developing other diseases that could have been avoided before they became a real problem. To this end, we are seeking to integrate new technologies into our portfolio within a single platform, both through our R&D efforts and through potential exclusive licenses or acquisitions." As the camera prototype nears completion, Avant is positioning itself for broader market entry. While a launch date has yet to be announced, the integrated platform is designed to reduce diagnostic friction, speed up referrals, and expand access to early-stage health insights — especially in geographies where affordability, not innovation, remains the primary barrier to care. With hardware now entering the pipeline, software validated in clinical settings, and corporate consolidation on the table, Avant is no longer just building an AI model — it's building a diagnostic system. Medtronic plc (NYSE: MDT) capped off its fiscal year with strong Q4 results, reporting $8.9 billion in revenue and double-digit earnings growth. "We had a strong close to our fiscal year, and I'm excited to see the progress we are making as our growth drivers continue to build momentum," said Geoff Martha, Chairman and CEO of Medtronic. "The underlying fundamentals of our business are strong, and they are getting stronger." The company highlighted progress across growth franchises, including the launch of BrainSense™ Adaptive Deep Brain Stimulation (aDBS) — its largest-ever commercial rollout of brain-computer interface technology, a milestone in precision neuromodulation. Additionally, Medtronic's AiBLE™ spine surgery ecosystem and connected insulin delivery platforms further signal its growing focus on AI-integrated healthcare solutions. Butterfly Network, Inc. (NYSE: BFLY) kicked off 2025 with strong execution, growing Q1 revenue 20% year-over-year to $21.2 million and narrowing its net loss to $14 million. "2025 is off to a great start. The Butterfly team hit the mark again, delivering right on target with a 20% growth quarter," said Joseph DeVivo, President, CEOah and Chairman of Butterfly Network. "We're very proud of how the Company continues to mature." The company advanced its Butterfly HomeCare pilot program and added two new AI developers to its Butterfly Garden, while existing partner DESKi secured FDA clearance for its AI-driven HeartFocus cardiac app. Its portable iQ3 ultrasound device continued gaining traction, featured on HBO Max's The Pitt and adopted by major U.S. med schools. With a strengthened balance sheet and increasing AI integration, Butterfly reiterated guidance for $96–100 million in 2025 revenue. Oracle Corporation (NYSE: ORCL), through its subsidiary Oracle Health, in partnership with Cleveland Clinic and G42, has announced a strategic collaboration to develop a global AI-powered healthcare delivery platform. The initiative will combine Oracle's cloud and AI infrastructure with Cleveland Clinic's clinical expertise and G42's advanced AI models to deliver scalable, secure, and affordable care. "Aging populations, rising costs, and the complexity of care demand a complete reinvention of how healthcare is provided," said Larry Ellison, Executive Chairman and CTO of Oracle. " Oracle's AI Data Platform and suite of clinical applications can help us understand disease and population health in ways that fuel scientific breakthroughs, reduce the cost of care delivery, and improve patient care. Together with Cleveland Clinic and G42, we will deliver the modern tools providers need to help people live longer, healthier lives." Designed to support precision medicine and real-time clinical intelligence, the platform aims to improve outcomes while reducing costs across the U.S., UAE, and beyond. Recursion Pharmaceuticcals, Inc. (NASDAQ: RXRX) announced early Phase 2 results from its TUPELO trial evaluating REC-4881 in patients with Familial Adenomatous Polyposis (FAP), a rare genetic disorder with no approved therapies. "For patients with FAP, who currently lack FDA-approved treatment options, Recursion's AI-powered Recursion OS platform identified a promising approach through MEK 1/2 inhibition," said Najat Khan, PhD, Chief R&D Officer and Chief Commercial Officer at Recursion. "By analyzing cellular models of APC gene loss, we uncovered a potential first-in-disease treatment and are excited to share our preliminary findings." The AI-discovered MEK1/2 inhibitor reduced polyp burden by a median of 43% in just 13 weeks among evaluable patients, with 83% showing clinical response. The study also reported improvements in upper GI disease severity and a manageable safety profile consistent with known MEK inhibitors. REC-4881 was developed through Recursion's in-house AI platform, Recursion OS, which analyzed APC gene loss models to generate a novel treatment pathway. CONTACT: Equity Insider [email protected] (604) 265-2873 DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. Equity Insider is a wholly-owned subsidiary of Market IQ Media Group, Inc. ("MIQ"). MIQ has been paid a fee for Avant Technologies Inc. advertising and digital media from the company directly. There may be 3rd parties who may have shares Avant Technologies Inc., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ own shares of Avant Technologies Inc. which were purchased in the open market. MIQ reserves the right to buy and sell, and will buy and sell shares of Avant Technologies Inc. at any time thereafter without any further notice. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material disseminated by MIQ has been approved by the above mentioned company; this is a paid advertisement, and we own shares of the mentioned company that we will sell, and we also reserve the right to buy shares of the company in the open market, or through other investment vehicles. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.
Cision Canada
26 minutes ago
- Cision Canada
FuelPositive Announces Reinstatement of Trading
TORONTO, June 4, 2025 /CNW/ - FuelPositive Corporation (TSXV: NHHH) (OTCQB: NHHHF) (" FuelPositive" or the " Company") announces that its common shares will be reinstated for trading on the TSX Venture Exchange at the open of markets on or about June 6, 2025. The Company was delayed in filing its annual audited financial statements for the fiscal year ended September 30, 2024, which were due on January 30, 2025. As a result, the Ontario Securities Commission issued a Cease Trade Order (" CTO") on February 3, 2025. The annual audited financial statements and accompanying management's discussion and analysis and officer certifications were completed shortly thereafter, and the CTO was revoked on February 24, 2025. The Company then entered the TSX Venture Exchange's standard reinstatement review process. Annual General Meeting The Company also announces that it intends to convene an annual general meeting (the " Meeting") of shareholders to be held prior to the end of August 2025. The most recent annual general meeting was held on July 12, 2023. Plans for the upcoming Meeting are currently underway and will be announced shortly. The policies of the TSX Venture Exchange require the Company to hold an annual general meeting in each calendar year and no longer than fifteen months from the previous meeting. Due to unexpected disruptions and challenging circumstances, the Company was unable to meet this timing requirement in 2024. The Company confirms that the non-brokered private placement previously announced on December 4, 2024, was interrupted and the offering's planned timeline was impacted by the duration of the reinstatement review process following the lifting of the CTO, and as a result has expired. The Company previously received advances towards the private placement totaling $621,000. The Company intends to settle these advances through the issuance of units of the Company on terms to be determined based on prevailing market conditions at the time. Completion of any settlement remains subject to the approval of the TSX Venture Exchange. With reinstated trading, the Company intends to launch a new private placement to raise the working capital needed to support strategic growth. The size and terms of the offering will be determined based on prevailing market conditions and company priorities at the time of launch. Corporate Communications Engagement The Company also confirms, further to its news release of February 25, 2021, that RB Milestone Group LLC (" RBMG") is engaged by the Company to provide corporate communications and investor relations advisory services on an ongoing basis. RBMG is a US-based corporate communications firm that specializes in investor relations advisory. RBMG is currently engaged on a month-to-month basis, for which it is entitled to receive a monthly cash fee of US$10,813. The Company is at arms-length to RBMG, and compensation of RBMG does not include any securities of the Company. To the knowledge of the Company, RBMG does not have any interest, directly or indirectly, in the securities of the Company. Media Strategy Engagement At the request of the TSX Venture Exchange, the Company also confirms that it previously engaged Quantum Ventures SEZC (" Quantum") to advise on media creation and online awareness strategies. Quantum provides media, awareness and strategic consulting services. Quantum was engaged for an initial twelve-month term, expiring April 2025, in consideration for a one-time fee of US$100,000. The engagement, which was undertaken in preparation for the activation of the Company's first ammonia production system, was affected by delays in the system's launch and has since concluded. The Company is at arms-length to Quantum, and compensation of Quantum did not include any securities of the Company. Partnership Development Services The Company engaged Planet Ventures Inc. (" Planet"), an arm's-length party, to support strategic partnership development and facilitate key stakeholder introductions in Manitoba. These services were intended to increase brand visibility in anticipation of the Company's green ammonia system becoming operational by the end of July 2024. While initial work began as planned, the Company had to pause the balance of services until the system is commercially ready, ensuring maximum impact upon resumption of services. As a result, the Company holds a service credit on reserve with Planet in the amount of $453,750, ready to be deployed in alignment with system launch. This amount was originally miscatagorized and has been reclassified as a prepaid expense in the interim financial statements for the six-month period ended March 31, 2025. Corporate Governance As part of its continued commitment to best practices in governance and transparency, and in preparation for the significant scaling of its operations, the Company is building upon its corporate framework with the formal adoption of a Related Party Transactions Policy and a Corporate Disclosure Policy. These policies build on the Company's existing internal practices and reflect its proactive approach to maintaining strong governance as the Company grows. About FuelPositive: Groundbreaking AgTech and Green Energy: FuelPositive's containerized Green Ammonia systems are redefining the ammonia industry by decentralizing production and placing control directly in the hands of farmers. This innovative model enables on-site generation of green nitrogen fertilizer and carbon-free fuel, reducing dependence on volatile supply chains and pricing. Each ton of ammonia produced by a FuelPositive system eliminates up to 2 tons of CO₂e emissions, offering both environmental and economic advantages. Designed for simplicity, reliability, and remote monitoring, the systems integrate seamlessly into farm operations, allowing farmers to produce what they need and when needed, without added complexity. First System Delivery: A Milestone in Sustainable Agriculture: In June 2024, FuelPositive delivered its first commercial demonstration system, the FP300, to Tracy and Curtis Hiebert's 11,000-acre grain farm near Sperling, Manitoba. This milestone marks a major advancement for both the Company and the future of sustainable agriculture. The upcoming system activation will further highlight the transformative impact of FuelPositive's technology on farming practices, supporting a more resilient and sustainable food system. Manitoba: A Global Center of Excellence: FuelPositive is positioning Manitoba at the forefront of decentralized Green Ammonia production. With a bold vision to establish a world-leading manufacturing hub in the province, the Company is set to drive economic growth, create high-value jobs in engineering, science, and skilled trades, and make Manitoba a global centre of excellence for sustainable agriculture and clean technology. FuelPositive Corporation is based in Ontario and Manitoba (Canada) and trades on the TSX Venture Exchange under the symbol NHHH and on the OTCQB in the USA under the symbol NHHHF. For further information, please contact: Ian Clifford Co-Founder, Chief Executive Officer and Board Chair [email protected] Tel: 416.535.8395 Investor Relations United States & International: RB Milestone Group (RBMG) [email protected] Investor Relations Canada: Transcend Capital Inc. Cautionary Statement Trading in the securities of the Company should be considered highly speculative. No stock exchange, securities commission or other regulatory authority has approved or disapproved the information contained herein. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accept responsibility for the adequacy or accuracy of this release. Forward-Looking Statements This news release contains certain "forward-looking information" and "forward-looking statements" (collectively, "forward-looking statements") that are based on expectations, estimates and projections as of the date of this news release. The information in this release about future plans and objectives of the Company are forward-looking statements. These forward-looking statements are based on assumptions and estimates of management of the Company at the time they were made and involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable by the Company as of the time of such statements, are inherently subject to significant business, economic and competitive uncertainties and contingencies. These estimates and assumptions may prove to be incorrect. Many of these uncertainties and contingencies can directly or indirectly affect and could cause, actual results to differ materially from those expressed or implied in any forward-looking statements. There can be no assurance that forward-looking information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Forward-looking information is provided to provide information about management's expectations and plans relating to the future. The Company disclaims any intention or obligation to update or revise any forward-looking information or to explain any material difference between subsequent actual events and such forward-looking information, except to the extent required by applicable law.
Globe and Mail
an hour ago
- Globe and Mail
3 surprising market winners in 2025
Investors brave enough to peek at their account statements know that it's been a rocky 2025. Even before tariff-related volatility, DeepSeek AI's launch clouded the major technology theme that powered the market in 2023 and 2024, as AI stocks entered a bear market in March. But there have been equity gains to be had in 2025. When I look at year-to-date returns across indexes, I notice a few surprising stars: European stocks, Latin America, and real estate investment trusts. The common thread that connects the three? All had been underperformers in prior years. European stocks have been made great again Morningstar's European stock index is riding high this year, as the macroeconomic environment has been improving. The financial-services sector, in particular, is a key beneficiary. Then there's Germany's newfound interest in deficit spending and the continent's focus on military self-sufficiency, spurred by the Donald Trump administration. US tariff announcements caused sharp selloffs in Europe, but the recovery has been V-shaped. A weakening US dollar has magnified European equity gains for unhedged US investors. It doesn't hurt that the European Central Bank and the Bank of England have actually been cutting interest rates. My research and investment colleagues have called Europe 'the most attractive developed-markets region globally,' making European stocks worthy of inclusion in a diversified portfolio. Latin America: Can the revival last? South of the US border, stocks are rallying. Morningstar's Latin American equities index is up more than 22% so far in 2025, thanks to Brazil, Mexico, and the smaller markets of Colombia and Chile. Here, too, a weakening dollar has boosted equity returns for unhedged US investors. This marks quite a turnaround from losses of more than 25% in US dollar terms in 2024. Brazil, for its part, faces serious fiscal challenges. In Mexico, sentiment was dented by election results on both sides of the border. Coming into the year, my colleagues on Morningstar's research and investment team identified Brazil as the highest potential global equity market for the coming 10 years. Latin American stocks are volatile but could hold more upside. REITs, especially those outside the US, outperform Real estate investment trusts are also up double digits this year outside the US. Property sectors in many geographies are vibrant, bolstered by low or falling interest rates. What about the US? The Morningstar US REIT Index is well behind the Morningstar Global Markets ex-US REIT Index in 2025, but it's in positive territory, ahead of the broad US equity market. US interest rates that appear to be staying higher for longer are seen as a negative for real estate. That said, REIT yields are attractive, and property is a 'real asset' that can act as an inflation hedge. Diversification assures exposure to unloved asset classes US mega-cap technology-oriented stocks did so well for so long that many investors thought they were the only game in town. Coming into 2025, it was hard to envision how the Magnificent Seven could ever be knocked off their perch. The rise of artificial intelligence, widely viewed as 'bigger than the internet,' seemed inexorable. No one saw DeepSeek AI coming, and few predicted the degree to which tariffs would disrupt. Gravity is a powerful force in investing, too. US stocks, especially on the growth side of the market, posted returns in 2023 and 2024 that far exceeded their historical levels. Their losses in 2025 can be seen as a reversion to the mean, or a return to long-term averages. The surprising winners of 2025 show that investment performance is dynamic. Contrarian bets can be profitable, though they can also take time to pay off. Investors who diversify by geography, style, and market capitalization are also well placed to benefit from leadership change. ___
